Regeneron Pharmaceuticals will release its second-quarter earnings next month, and analysts anticipate a double-digit profit ...

The market expects Regeneron (REGN) to deliver a year-over-year decline in earnings on lower revenues when it reports results ...

Investors will focus on profits from asthma drug Dupixent and sales of Eylea HD when biotech giant Regeneron Pharmaceuticals, ...

Earnings season begins this week. With the tariff overhang and higher expectations for coming quarters, forward earnings guidance from management will be crucial.

Whales with a lot of money to spend have taken a noticeably bullish stance on Regeneron Pharmaceuticals. Looking at options history for Regeneron Pharmaceuticals REGN we detected 14 trades. If we ...

26 analysts have shared their evaluations of Regeneron Pharmaceuticals REGN during the recent three months, expressing a mix of bullish and bearish perspectives. In the table below, you'll find a ...

Wall Street expects a year-over-year decline in earnings on higher revenues when United Airlines (UAL) reports results for the quarter ended June 2025. While this widely-known consensus outlook is ...

It may be a year later than originally planned, but Regeneron Pharmaceuticals Inc. is set to commercialize Lynozyfic (linvoseltamab) in the U.S. following FDA approval for use in adults with relapsed ...

NET PROFIT: Seven & i's net profit is expected to have risen 50% to 32.2 billion yen, equivalent to $219.7 million, for the three months ended May, according to a poll of analysts by Visible Alpha ...